Updated clinical perspectives and challenges of chimeric antigen receptor-T cell therapy in colorectal cancer and invasive breast cancer
In recent years, the incidence of colorectal cancer (CRC) and breast cancer (BC) has
increased worldwide and caused a higher mortality rate due to the lack of selective anti …
increased worldwide and caused a higher mortality rate due to the lack of selective anti …
Classical angiogenic signaling pathways and novel anti-angiogenic strategies for colorectal cancer
M Cao, Y Wang, G Lu, H Qi, P Li, X Dai… - Current Issues in Molecular …, 2022 - mdpi.com
Although productive progress has been made in colorectal cancer (CRC) researchs, CRC is
the second most frequent type of malignancy and the major cause of cancer-related death …
the second most frequent type of malignancy and the major cause of cancer-related death …
A systematic review and meta-analysis of trifluridine/tipiracil plus bevacizumab for the treatment of metastatic colorectal cancer: evidence from real-world series
IA Voutsadakis - Current Oncology, 2023 - mdpi.com
Background: Colorectal cancer is the most prevalent gastrointestinal neoplasm. When
metastatic, the disease has limited systemic treatment options. Novel targeted therapies …
metastatic, the disease has limited systemic treatment options. Novel targeted therapies …
Innovations in colorectal cancer treatment: trifluridine and tipiracil with bevacizumab for improved outcomes–a review
T Rais, R Riaz, T Siddiqui, A Shakeel… - Frontiers in …, 2024 - pmc.ncbi.nlm.nih.gov
Colorectal cancer ranks second in cancer-related deaths throughout the world. At the time of
diagnosis, at least 20% of the patients with CRC had already developed metastases …
diagnosis, at least 20% of the patients with CRC had already developed metastases …
Combining moderate dosage of Bevacizumab with TAS-102 provides longer progression-free time in refractory metastatic colorectal Cancer
KY Tseng, MY Yang, WS Chen, JK Jiang… - International Journal of …, 2024 - Springer
Purpose We aimed to evaluate the efficacy of moderate doses of bevacizumab in
combination with TAS-102 for the treatment of refractory metastatic colorectal cancer …
combination with TAS-102 for the treatment of refractory metastatic colorectal cancer …
[HTML][HTML] Bevacizumab mitigates codon-specific effects of trifluridine/tipiracil on efficacy outcome parameters in metastatic colorectal cancer
Background Molecular informed therapy changed treatment patterns of metastatic colorectal
cancer (mCRC). Recently KRAS G12, the most prevalent RAS mutation in mCRC, was …
cancer (mCRC). Recently KRAS G12, the most prevalent RAS mutation in mCRC, was …
RETRO-TAS, a Retrospective Observational Study of Trifluridine/Tipiracil in Chemorefractory Metastatic Colorectal Cancer
A Koumarianou, A Ntavatzikos, D Symeonidis… - Biomedicines, 2023 - mdpi.com
Background: Trifluridine/tipiracil (FTD/TPI) is an oral antimetabolite agent comprised of
trifluridine, a thymidine-based nucleoside analogue that inhibits cell proliferation following …
trifluridine, a thymidine-based nucleoside analogue that inhibits cell proliferation following …
Combination of Modest Dosage of Bevacizumab with TAS-102 Provided the Comparable Efficacy in Treating Refractory Metastatic Colorectal Cancer
KY Tseng, MY Yang, WS Chen, JK Jiang, HS Wang… - 2024 - researchsquare.com
Background Given that the combination of bevacizumab and TAS-102 is used to treat
refractory metastatic colorectal cancer (mCRC), we aimed to evaluate the efficacy of modest …
refractory metastatic colorectal cancer (mCRC), we aimed to evaluate the efficacy of modest …